Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS

(NOVN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novartis : and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasis

share with twitter share with LinkedIn share with facebook
share via e-mail
02/25/2020 | 02:39am EDT
  • LXE408 is a first-in-class compound, discovered at Novartis with financial support from the Wellcome Trust
  • Novartis is responsible for completing Phase I clinical trials and has committed to maximizing access in endemic countries, once approved
  • DNDi will lead Phase II and III clinical development, starting in India with additional trials planned in East Africa
  • Leishmaniasis, which is transmitted by the sand fly, affects over one billion people; visceral leishmaniasis, the most serious form of the disease, affects an estimated 50 000 to 90 000 people per year

Basel, February 25, 2020 - Novartis and the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development (R&D) organization, have signed a collaboration and licence agreement to jointly develop LXE408, as a potential new oral treatment for visceral leishmaniasis, one of the world's leading parasitic killers.

LXE408 is a first-in-class compound, discovered at Novartis with financial support from the Wellcome Trust. Within the scope of the agreement, Novartis is responsible for completing Phase I clinical trials. In addition, it will drive pharmaceutical development and regulatory submissions. Upon approval, Novartis has committed to distributing the drug on an affordable basis worldwide with a focus on maximizing access in endemic countries.

DNDi will lead Phase II and Phase III clinical development, with the first Phase II study scheduled to start in early 2021 in India. Additional trials are planned to take place in East Africa, which has the highest burden of visceral leishmaniasis.

'Existing treatments for visceral leishmaniasis are simply not good enough. They are too long, increasingly ineffective, and can be toxic, painful, and costly,' said Dr Bernard Pécoul, Executive Director of DNDi. 'Our hope is to radically transform this by developing new oral drugs that are affordable, safe, effective, easy to take, and can also be adapted to meet the treatment needs of patients in different countries.'

Over one billion people worldwide are at risk of leishmaniasis, which is transmitted by the bite of a sand fly. Visceral leishmaniasis, also known as kala-azar, is the most serious form of leishmaniasis, causing fever, weight loss, spleen and liver enlargement, and if left untreated, death. There are an estimated 50 000 to 90 000 new cases per year. Treating the disease is complex as it is dependent on the species of infecting parasite and the country, as treatment responses differ from region to region.

'Novartis has a long-term commitment to neglected tropical diseases that spans several decades. Diseases caused by kinetoplastid parasites, such as leishmaniasis, are one of our strategic research priorities and, together with our partners, we have developed a promising portfolio of drug candidates,' said Dr Lutz Hegemann, Chief Operating Officer for Global Health at Novartis. 'We are excited to collaborate with DNDi to reimagine treatment options for people with leishmaniasis around the world.'

Broader partnerships
The collaboration between DNDi and Novartis is aligned with a broader program with the Wellcome Trust and other partners to develop new combinations of entirely new, all-orally acting chemical entities, to treat visceral leishmaniasis and cutaneous leishmaniasis, another form of the disease.

The program brings together a strong consortium of R&D partners, including the University of Dundee, GSK, Pfizer, TB Alliance, and Takeda Pharmaceutical Company Limited. These partners have built a portfolio of lead series, pre-clinical and clinical drug candidates, originating from different chemical classes with different mechanisms of action against leishmania parasites.

'We are delighted to be partnering with Novartis from drug development to delivering a promising new oral treatment for visceral leishmaniasis. Together, we can contribute to sustaining elimination efforts in India and altering the treatment landscape in East Africa,' said Dr Fabiana Alves, Head of Visceral Leishmaniasis Clinical Program at DNDi.

Disclaimer
This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'plan,' 'expect,' 'anticipate,' 'look forward,' 'believe,' 'committed,' 'investigational,' 'pipeline,' 'launch,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this media update, or regarding potential future revenues from such products or regarding the collaboration described in this media update. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this media update will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee that the collaboration described in this media update will achieve any of its intended goals and objectives in the expected time frame, or at all. Nor can there be any guarantee that such products will be successful in the future. In particular, our expectations regarding such products and the collaboration described in this media update could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political and economic conditions; safety, quality, data integrity, or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this media update as of this date and does not undertake any obligation to update any forward-looking statements contained in this media update as a result of new information, future events or otherwise.

About Novartis
Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 145 nationalities work at Novartis around the world. Find out more at
www.novartis.com

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartisnews
For Novartis multimedia content, please visit www.novartis.com/news/media-library
For questions about the site or required registration, please contact [email protected]

About DNDi
A not-for-profit research and development organization, DNDi works to develop new treatments for people living with neglected diseases, notably Chagas disease, sleeping sickness (human African trypanosomiasis), leishmaniasis, filarial infections, mycetoma, pediatric HIV, and hepatitis C. Since its inception in 2003, DNDi has delivered eight new treatments, including new drug combinations for kala-azar, two fixed-dose antimalarials, and DNDi's first successfully developed new chemical entity, fexinidazole, approved in 2018 for the treatment of both stages of sleeping sickness.

# # #

Novartis Media Relations
E-mail: [email protected]

Antonio Ligi
Novartis External Communications
+41 61 324 1374 (direct)
[email protected]

Eric Althoff
Novartis US External Communications
+1 646 438 4335
[email protected]

Katerina Kontzalis
Global Health & CR Communications
+41 61 324 1631 (direct)
+41 79 797 8393 (mobile)
[email protected]

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: [email protected]

Central North America
Samir Shah +41 61 324 7944 Sloan Simpson +1 862 778 5052
Pierre-Michel Bringer
Thomas Hungerbuehler
Isabella Zinck
+41 61 324 1065
+41 61 324 8425
+41 61 324 7188
Cory Twining +1 862 778 3258

Disclaimer

Novartis AG published this content on 25 February 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 February 2020 06:38:10 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVARTIS
03/26NOVARTIS : ROSEN, A HIGHLY RANKED FIRM, Continues to Investigate Securities Clai..
BU
03/25NOVARTIS : AveXis - Zolgensma data shows rapid, significant, clinically meaningf..
AQ
03/24NOVARTIS : Sandoz acquires US distribution rights to two key hospital injectable..
AQ
03/23NOVARTIS : Sandoz Gets U.S. Distribution Rights for Two Hospital-Injectable Medi..
DJ
03/23NOVARTIS : commits to donate up to 130 million doses of hydroxychloroquine to su..
AQ
03/20NOVARTIS : to Donate Drug in Coronavirus Fight
DJ
03/20NOVARTIS : receives approval from Japanese Ministry of Health, Labour and Welfar..
AQ
03/19NCLAT Affirms That The De Minimis Exemption Should Have Always Applied To The..
AQ
03/17NOVARTIS : Joins R&D Efforts, Sets Up $20 Million Fund to Combat Coronavirus
DJ
03/13NOVARTIS : secures alternate options for Kymriah shipments after Europe travel b..
RE
More news
Financials (USD)
Sales 2020 50 040 M
EBIT 2020 14 984 M
Net income 2020 9 396 M
Debt 2020 19 663 M
Yield 2020 3,89%
P/E ratio 2020 19,0x
P/E ratio 2021 16,4x
EV / Sales2020 4,01x
EV / Sales2021 3,70x
Capitalization 181 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 101,26  $
Last Close Price 79,88  $
Spread / Highest target 57,0%
Spread / Average Target 26,8%
Spread / Lowest Target -7,40%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS-16.30%180 007
JOHNSON & JOHNSON-13.23%324 693
ROCHE HOLDING AG-5.29%264 026
MERCK & CO., INC-21.13%181 927
PFIZER, INC.-21.13%171 422
NOVO NORDISK A/S-0.69%133 274